Evidence map›Paper›PMID 41373499›Full record

ArticleInternational journal of molecular sciences2025

Development of Norrin-Based Protein Therapeutic for Activation of Norrin-Wnt Signaling in Human Retinal Endothelial Cells.

Kenneth P Mitton, Wendy A Dailey, Steven Q Krikor, Kimberly A Drenser

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kenneth P MittonEye Research Institute, Oakland University, Rochester, MI 48309, USA.ORCID 0000-0002-4751-7440
Wendy A DaileyRetiNova Therapeutics, San Diego, CA 94402, USA.
Steven Q KrikorEye Research Institute, Oakland University, Rochester, MI 48309, USA.
Kimberly A DrenserRetiNova Therapeutics, San Diego, CA 94402, USA.

Funding

Noregen, a regenerative medicine ocular therapeuticR44EY030807 · NEI · RETINAL SOLUTIONS LLC · PI DRENSER, KIMBERLY · 2023 to 2024
$1.4M
Noregen(TM), a regenerative medicine ocular therapeuticR41EY030807 · NEI · RETINAL SOLUTIONS LLC · PI MITTON, KENNETH PATRICK · 2019 to 2019
$227k
NEI NIH HHS R41 EY030807NEI NIH HHS R41EY030807NEI NIH HHS R44 EY030807
6 · The paper itself

Abstract

Norrin-Wnt signaling is essential for retinal vascular development and generation of the inner blood retinal barrier. Norrin itself is a potential therapeutic for retinal vascular repair. We explored the feasibility of producing a recombinant protein therapeutic based on human Norrin for intravitreal injection. Norrin

Indexed as

Endothelial CellsEye ProteinsNerve Tissue ProteinsRetinaWnt Signaling PathwayAnimalsAxin ProteinFrizzled ReceptorsHumansIntravitreal InjectionsMaleRatsAxin ProteinEye ProteinsFrizzled ReceptorsFZD4 protein, humanNDP protein, humanNerve Tissue Proteinsblood retinal barrierendothelial cellsNorrinprotein therapeuticrecombinant proteinretinal vascular diseasetherapeutic developmentWnt signaling

Identifiers

PMID41373499
PMCPMC12692543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.